The adrenal glands are small, triangular-shaped endocrine glands located on top of each kidney. Each gland consists of two distinct parts: the outer cortex and the inner medulla, each producing different hormones. The adrenal cortex is further divided into three zones, each producing specific steroid hormones. The zona glomerulosa, the outermost layer, is responsible for aldosterone production. This zone responds primarily to angiotensin II and potassium levels rather than ACTH, which regulates the other cortical zones.

The RAAS is a complex hormone system that regulates blood pressure and fluid balance. Normally, when blood pressure falls, the kidneys release renin, which converts angiotensinogen to angiotensin I. Angiotensin-converting enzyme (ACE) then converts angiotensin I to angiotensin II, a potent vasoconstrictor that also stimulates aldosterone release from the adrenal glands. Aldosterone then acts on the kidneys to increase sodium and water reabsorption, increasing blood volume and blood pressure. In primary aldosteronism, this feedback loop is disrupted - aldosterone is produced independently of renin, leading to unchecked sodium retention and potassium loss.

The cardiovascular system is profoundly affected by excess aldosterone. Beyond hypertension, patients with primary aldosteronism experience increased left ventricular hypertrophy, endothelial dysfunction, and vascular remodeling. These changes increase the risk of myocardial infarction, stroke, and atrial fibrillation. The cardiovascular risk remains elevated even compared to patients with essential hypertension of similar blood pressure levels, suggesting that aldosterone itself has direct damaging effects on the heart and blood vessels independent of blood pressure elevation.

The kidneys are both the target of aldosterone action and ultimately affected by its excess. Aldosterone acts on the distal convoluted tubule and collecting duct to increase sodium reabsorption in exchange for potassium and hydrogen ion excretion. This leads to increased blood volume (raising blood pressure) and potassium loss (causing hypokalemia). Chronic potassium depletion can lead to renal damage, including interstitial nephritis and impaired renal function. The kidneys become less able to concentrate urine, contributing to polyuria and nocturia.

Metabolic disturbances in primary aldosteronism extend beyond potassium to affect multiple systems. Glucose intolerance and insulin resistance are more common in patients with primary aldosteronism, increasing the risk of type 2 diabetes. Metabolic alkalosis results from hydrogen ion loss in exchange for potassium. These metabolic effects generally improve with effective treatment of aldosterone excess. Understanding these systemic effects is crucial for comprehensive management at Healers Clinic Dubai.

Primary aldosteronism is classified based on the underlying cause, which directly determines treatment approach and prognosis.

Aldosterone-producing adenoma, also termed Conn's tumor, represents the classic cause of primary aldosteronism and accounts for approximately 30-40% of cases. These benign tumors arise from the zona glomerulosa of the adrenal cortex and autonomously produce aldosterone, independent of normal regulatory mechanisms. APAs are typically small (less than 2 cm in diameter) and are more common in younger patients. The tumor cells contain specific mutations (particularly in the KCNJ5 gene) that drive autonomous aldosterone production. Surgical removal of the adenoma often results in complete cure of the condition, making accurate localization essential.

Bilateral adrenal hyperplasia, also known as idiopathic hyperaldosteronism, accounts for approximately 60-70% of cases of primary aldosteronism. This condition involves enlargement (hyperplasia) of both adrenal glands with increased aldosterone production from multiple foci. The pathophysiology involves dysregulation of adrenal steroidogenesis rather than a discrete tumor. Bilateral disease is more common in older patients and tends to have a less severe phenotype compared to aldosterone-producing adenomas. Treatment focuses on medical management with mineralocorticoid receptor antagonists rather than surgery.

Familial forms of hyperaldosteronism, though rare, are important to recognize due to their genetic basis and implications for family screening. Four types have been identified:

• Type I (Glucocorticoid-Remediable Aldosteronism): A hybrid gene from unequal crossing over causes ACTH-driven aldosterone production
• Type II: Familial aldosterone-producing adenomas or hyperplasia without glucocorticoid suppressibility
• Type III: Mutations in KCNJ5 channels causing severe aldosterone excess
• Type IV: Mutations in CACNA1H channels

Genetic testing helps identify these hereditary forms, which may require different treatment approaches and warrant family screening.

Several rare causes of primary aldosteronism warrant consideration in specific clinical scenarios. Adrenal carcinoma (adrenal cortical carcinoma) producing aldosterone is extremely rare but aggressive. Unilateral adrenal hyperplasia represents another rare cause. Ectopic aldosterone-producing tumors have been reported in rare instances. Our comprehensive diagnostic approach at Healers Clinic ensures thorough evaluation to identify these uncommon etiologies when indicated.

The identification of specific genetic mutations has revolutionized understanding of primary aldosteronism pathogenesis. Somatic mutations in the KCNJ5 gene (encoding a potassium channel) are found in approximately 40% of aldosterone-producing adenomas. These mutations cause depolarization of adrenal cells, leading to calcium influx and autonomous aldosterone production. Other genes implicated include ATP1A1, ATP2B3, CACNA1D, and CTNNB1. Germline mutations cause familial forms. These genetic discoveries have diagnostic and therapeutic implications.

The development of aldosterone-producing adenomas involves complex interactions between genetic predisposition and environmental factors. While the exact triggers are not fully understood, factors promoting tumor growth include prolonged stimulation of the adrenal cortex and dysregulated cell growth pathways. Understanding whether a tumor is sporadic or hereditary helps guide family screening and treatment decisions.

In many cases, no discrete tumor is identified, and bilateral adrenal hyperplasia results from dysregulation of normal adrenal steroidogenesis. This may involve enhanced sensitivity to angiotensin II, disordered intracellular signaling, or adrenal cell hyperplasia. The exact mechanisms remain an active area of research, but the result is excessive aldosterone production from both adrenal glands.

Resistant hypertension, defined as blood pressure that remains above target despite concurrent use of three antihypertensive agents of different classes, is a major risk factor for primary aldosteronism. Studies suggest that 20-30% of patients with resistant hypertension have primary aldosteronism. Anyone with difficult-to-control blood pressure should be evaluated for this condition.

Hypertension developing at a young age (generally under 30 years) warrants evaluation for secondary causes including primary aldosteronism. While essential hypertension can certainly occur in young adults, the presence of primary aldosteronism in this population is often missed.

Spontaneous hypokalemia (low potassium without diuretic use) or hypokalemia that is severe or difficult to correct is a classic red flag for primary aldosteronism. However, it's important to note that many patients with primary aldosteronism have normal potassium levels, particularly in early disease or with bilateral hyperplasia.

An adrenal incidentaloma (an adrenal mass discovered incidentally on imaging done for other reasons) warrants evaluation for hormonal excess, including primary aldosteronism. The likelihood of the mass being functional increases with size.

A family history of early-onset hypertension or confirmed primary aldosteronism increases risk. Rare familial forms should be considered, especially when multiple family members are affected.

Certain ethnic groups may have different prevalences of primary aldosteronism. Research is ongoing regarding variations in prevalence across different populations.

Hypertension is the cardinal manifestation of primary aldosteronism and is present in virtually all patients with the condition. The blood pressure elevation can be severe and often resistant to conventional antihypertensive medications. Patients may present with blood pressure values significantly above targets, sometimes exceeding 180/110 mmHg. Unlike essential hypertension, the hypertension in primary aldosteronism is often accompanied by low potassium and other metabolic abnormalities. The hypertension results from sodium and water retention increasing blood volume, along with direct effects of aldosterone on vascular smooth muscle.

Hypokalemia, or low serum potassium, is a classic but not universal feature of primary aldosteronism. Only approximately 30-40% of patients with primary aldosteronism have clinically significant hypokalemia at presentation, though potassium levels may be in the low-normal range in others. When present, hypokalemia can cause muscle weakness, fatigue, cramping, and occasional paralysis. Cardiac arrhythmias are a serious complication of severe hypokalemia. Patients may also experience polyuria (excessive urination) and polydipsia (excessive thirst) due to the renal effects of potassium loss.

Muscle weakness in primary aldosteronism is typically related to hypokalemia. Potassium is essential for normal muscle function, and low levels can cause weakness ranging from mild fatigue to profound weakness that can mimic periodic paralysis. The weakness often affects the legs more than the arms and may come and go.

Chronic fatigue is a common symptom, related to both hypokalemia and the metabolic effects of aldosterone excess. Patients may also experience difficulty concentrating and decreased exercise tolerance.

The cardiovascular consequences of primary aldosteronism extend far beyond hypertension alone. Patients have significantly increased risk of cardiovascular events including myocardial infarction, stroke, and atrial fibrillation compared to patients with essential hypertension of similar severity. Left ventricular hypertrophy is more severe and develops more rapidly than in other forms of hypertension. Heart failure may develop due to long-standing volume overload and hypertension. These complications underscore the importance of early diagnosis and aggressive treatment.

Frequent or severe headaches are commonly reported in patients with primary aldosteronism, related to the significant hypertension that characterizes this condition. These headaches may be particularly severe in the morning or associated with high blood pressure readings.

Patients with primary aldosteronism are at increased risk for cardiac arrhythmias, particularly atrial fibrillation. This risk is heightened by both hypokalemia and the direct effects of aldosterone on cardiac electrical activity. Palpitations may be reported.

Excessive urination and thirst are common, resulting from the renal effects of potassium loss. The kidneys are unable to properly concentrate urine, leading to large urine volumes and compensatory increased fluid intake.

Metabolic alkalosis results from hydrogen ion loss in exchange for potassium in the kidneys. This can cause symptoms including muscle twitching, cramping, and in severe cases, tetany.

Insulin resistance and glucose intolerance are more common in primary aldosteronism, increasing the risk of progression to type 2 diabetes. This metabolic disturbance improves with treatment of the underlying aldosterone excess.

At Healers Clinic Dubai, our comprehensive clinical assessment for suspected primary aldosteronism follows a systematic approach designed to ensure accurate diagnosis and appropriate treatment planning.

1. Initial Consultation

   • Detailed medical history including blood pressure patterns, symptoms, and family history
   • Review of current medications that may affect testing
   • Assessment of risk factors and clinical indicators

2. Physical Examination

   • Blood pressure measurement (multiple readings)
   • Assessment for signs of hypokalemia
   • Examination for acanthosis nigricans and other skin findings
   • Cardiovascular examination

3. Laboratory Investigation

   • Basic metabolic panel including potassium and sodium
   • Hormone panel including aldosterone and renin
   • Additional tests as needed based on initial findings

4. Diagnostic Testing

   • Screening tests (aldosterone-to-renin ratio)
   • Confirmatory testing as indicated
   • Imaging for subtype differentiation

5. Treatment Planning

   • Individualized treatment approach based on subtype
   • Integrative treatment planning incorporating complementary therapies

Screening for primary aldosteronism is recommended in specific high-risk populations, including patients with resistant hypertension, hypertension with spontaneous or diuretic-induced hypokalemia, early-onset hypertension (under age 30), and hypertension with adrenal incidentaloma. The preferred screening test is the aldosterone-to-renin ratio (ARR), calculated as plasma aldosterone concentration divided by plasma renin activity or direct renin concentration.

An elevated ARR suggests possible primary aldosteronism, though confirmatory testing is required. Screening should be performed after correcting hypokalemia and avoiding medications that significantly affect the renin-angiotensin system.

Confirmatory testing is required after positive screening to establish the diagnosis definitively. Several protocols exist:

• Saline Infusion Test: 2 liters of normal saline over 4 hours; aldosterone failing to suppress indicates primary aldosteronism
• Captopril Challenge Test: Single dose of captopril with subsequent aldosterone measurement
• Fludrocortisone Suppression Test: Gold standard but rarely performed due to complexity

Testing must be performed under standardized conditions with attention to medication effects, potassium levels, and dietary sodium intake.

Distinguishing between unilateral and bilateral disease is essential for determining appropriate treatment.

Beyond aldosterone and renin measurement, additional laboratory tests provide important diagnostic information:

• Serum electrolytes (potassium, sodium, bicarbonate)
• Fasting glucose and HbA1c
• Lipid panel
• Complete blood count
• Adrenal hormone panel

The most common differential diagnosis is essential (primary) hypertension, which has no identifiable cause. While both conditions present with elevated blood pressure, essential hypertension is not associated with hypokalemia, suppressed renin, or elevated aldosterone. The key distinguishing feature is the autonomous nature of aldosterone production in primary aldosteronism.

Secondary aldosteronism results from activation of the renin-angiotensin system in response to conditions like:

• Heart failure
• Liver cirrhosis with ascites
• Renal artery stenosis
• Diuretic use
• Effective volume depletion

In secondary aldosteronism, both renin and aldosterone are elevated, unlike primary aldosteronism where renin is suppressed.

Hypokalemia in a hypertensive patient requires consideration of other causes:

• Diuretic use (most common)
• Cushing's syndrome
• Liddle syndrome (rare genetic disorder)
• Apparent mineralocorticoid excess (AME)
• Licorice ingestion

Other adrenal conditions that may present similarly include:

• Pheochromocytoma (causes intermittent hypertension)
• Cushing's syndrome (causes hypertension and hypokalemia)
• Adrenal incidentalomas (may be non-functional)

Surgical removal of the affected adrenal gland (adrenalectomy) offers potential cure for patients with unilateral aldosterone-producing adenoma or unilateral hyperplasia.

Preoperative preparation includes normalization of blood pressure and potassium levels with mineralocorticoid receptor antagonists. Most patients experience significant improvement or normalization of blood pressure postoperatively, though some may require continued antihypertensive therapy. Hypokalemia typically resolves completely.

Medical therapy is the primary treatment for bilateral adrenal hyperplasia and for patients who are not surgical candidates.

Additional antihypertensive medications are often required to achieve blood pressure targets. Treatment is typically lifelong, and ongoing monitoring is essential.

The choice between surgery and medication depends on:

• Disease subtype (unilateral vs bilateral)
• Patient preference
• Surgical risk
• Age and comorbidities

At Healers Clinic Dubai, constitutional homeopathy addresses individual symptom patterns and constitutional type. Treatment is selected based on the patient's complete symptom picture, including:

• Blood pressure patterns and fluctuations
• Response to weather and temperature
• Energy levels and fatigue patterns
• Emotional and mental state
• Individual susceptibility

Constitutional homeopathy aims to support overall wellbeing and may help manage stress related to chronic illness.

Ayurvedic medicine provides comprehensive approaches to supporting cardiovascular health and hormonal balance:

• Herbal Formulations: Herbs including Arjuna (Terminalia arjuna), Ashwagandha (Withania somnifera), and Punarnava (Boerhavia diffusa) support cardiovascular function
• Dietary Guidance: Recommendations for kapha-pacifying diet appropriate for the patient's constitution
• Lifestyle Modifications: Daily routines (dinacharya) and seasonal regimens (ritucharya) to support balance
• Detoxification: Panchakarma therapies when appropriate

IV nutrition therapy delivers essential nutrients directly for optimal absorption:

• Magnesium: Supports cardiovascular function and helps manage blood pressure
• Vitamin C: Antioxidant support for vascular health
• B-Complex Vitamins: Energy metabolism and stress support
• Coenzyme Q10: Cardiovascular mitochondrial function

These integrative approaches work alongside conventional treatments to optimize outcomes and quality of life for patients with primary aldosteronism.

Sodium restriction is essential for managing primary aldosteronism:

• Limit daily sodium intake to less than 2,300 mg
• Read food labels carefully
• Avoid processed foods, restaurant meals, and canned foods
• Use herbs and spices instead of salt for flavor
• Be aware of hidden sodium in bread, cheese, and condiments

While not a substitute for medical treatment, dietary potassium supports repletion:

• Fruits: Bananas, oranges, melons, avocados
• Vegetables: Tomatoes, potatoes, spinach, broccoli
• Legumes: Beans, lentils
• Nuts and seeds

Note: Dietary potassium changes should be discussed with your physician, especially if taking potassium-sparing medications.

Ongoing monitoring is essential:

• Blood pressure tracking at home
• Regular electrolyte checks
• Medication adherence
• Follow-up appointments

Chronic stress can worsen blood pressure:

• Practice relaxation techniques
• Consider meditation or yoga
• Ensure adequate sleep
• Engage in regular physical activity

While primary aldosteronism is not preventable in the traditional sense, early detection prevents complications:

• Screening programs for high-risk populations
• Public awareness of hypertension
• Access to specialized endocrine care

For individuals with diagnosed primary aldosteronism, prevention focuses on:

• Preventing complications through early and adequate treatment
• Regular monitoring to ensure disease control
• Lifestyle modifications to reduce cardiovascular risk
• Medication adherence

For patients with familial forms of primary aldosteronism:

• Genetic counseling
• Family member screening
• Early intervention for affected relatives

The prognosis for patients with primary aldosteronism varies significantly based on subtype and treatment approach:

• Aldosterone-producing adenoma: 70%+ achieve complete cure with surgery
• Bilateral disease: Excellent control with medication in most cases
• Cardiovascular risk: Remains elevated even after treatment, requiring ongoing management

Early diagnosis and complete treatment lead to the best outcomes. Delayed treatment is associated with more persistent cardiovascular changes and worse long-term outcomes.

Patients with primary aldosteronism require lifelong follow-up:

• Blood pressure monitoring
• Serum potassium checks
• Renal function assessment
• Cardiovascular risk factor management
• Bone density monitoring (if on long-term spironolactone)

Our comprehensive care model at Healers Clinic ensures systematic follow-up and proactive management.

Q: Is primary aldosteronism curable?

A: Primary aldosteronism due to aldosterone-producing adenoma can be cured with surgical removal of the affected adrenal gland. Bilateral disease is managed medically but cannot be cured; however, it can be effectively controlled with appropriate treatment. Early diagnosis and complete treatment improve long-term outcomes.

Q: What is the difference between primary and secondary aldosteronism?

A: Primary aldosteronism results from adrenal overproduction of aldosterone independent of the renin-angiotensin system, with suppressed renin levels. Secondary aldosteronism occurs in response to activation of the renin-angiotensin system, as seen in conditions like heart failure, liver cirrhosis, or renal artery stenosis, with elevated renin levels.

Q: Can lifestyle changes cure primary aldosteronism?

A: Lifestyle modifications including sodium restriction are important adjuncts to treatment but cannot cure primary aldosteronism. Medical or surgical treatment is required to address the underlying aldosterone excess. Lifestyle changes support overall cardiovascular health and may improve treatment efficacy.

Q: How is adrenal vein sampling performed?

A: Adrenal vein sampling is a specialized procedure performed by interventional radiologists. Catheters are inserted through the groin and advanced to both adrenal veins. Blood samples are obtained from each adrenal vein and from a peripheral vein to measure aldosterone and cortisol levels. The procedure helps determine which adrenal gland is producing excess aldosterone.

Q: Will I need to take medication forever?

A: For patients with bilateral adrenal hyperplasia, lifelong medication is typically required. For those with aldosterone-producing adenoma treated surgically, many patients can achieve normal blood pressure without long-term medication. Some patients may still require blood pressure medication postoperatively.

Q: Does everyone with primary aldosteronism have low potassium?

A: No. Only about 30-40% of patients with primary aldosteronism have clinically significant hypokalemia at diagnosis. Many patients, especially those with bilateral hyperplasia, have normal potassium levels. The absence of hypokalemia does not exclude the diagnosis.

Document Information:

• Category: Endocrine
• Last Updated: 2026-03-09
• Provider: Healers Clinic Dubai

This content is for educational purposes only.

Contact us at +971 56 274 1787 or book online at https://healers.clinic/booking/